StockWatch
·

Dodla Dairy Ltd Q1 FY27 Results

DODLAQ1 FY27 Results
Filing
Result:Weak· Market: DownMargin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue1.2K Cr11.5%19.0%
Total Income1.2K Cr10.7%18.3%
Expenditure1.2K Cr10.8%22.7%
PBT54.70 Cr1.0%32.5%
Net Profit40.64 Cr41.7%35.4%
OPM5.42%0.12pp2.77pp
NPM3.35%3.02pp2.79pp
EPS6.7441.7%35.3%
View full financials

Revenue grew 19% YoY but adjusted PAT fell 35% as OPM compressed sharply from 8.2% to 5.4%, a clear miss on profitability for an FMCG/dairy name despite healthy top-line growth.

DODLA DAIRY · Q1 FY-2027 · THE VERDICT

Record revenue, profit collapse: the pricing lag that defines the quarter

Dodla's highest-ever revenue of ₹1,198 Cr masks a structural margin squeeze: PAT collapsed 35% YoY and EBITDA margin fell 280 basis points, driven by procurement cost inflation that management has only partially passed through. The recovery case hinges entirely on price-through success in Q2+, but execution credibility is now in question.

02 Aug 2026 · 6 min read
Revenue

₹1,198 Cr

Highest-ever; +19% YoY

Net Profit

₹41 Cr

-35% YoY

EBITDA Margin

5.4%

vs 8.2% prior year; -280 bps

Milk Procurement

21.1L liters/day

+13% YoY (record)

Dodla's Q1 earnings deliver a paradox: the highest-ever quarterly revenue and record milk procurement, yet PAT crashed 35% year-on-year and EBITDA margin fell 280 basis points. The headline number conceals a structural problem — not a quarter to hang recovery hopes on without seeing evidence of it first.

Where the profit went

Milk procurement costs surged ₹3.9 per liter year-on-year to ₹41.3/L (driven by El-Niño weather and low flush-season milk supply), but Dodla's milk selling prices rose only ₹2.2 per liter to ₹59.4/L. That's a 56% pass-through rate — meaning management absorbed 44% of the cost inflation directly into margin. Gross margin compressed 260 basis points to 23.2%, and PAT margin fell 280 basis points to 5.4%. Management attributes this to seasonal/cyclical pressure and says the worst is behind. But the call reveals reactive pricing, not proactive. The ₹2/L milk hike and ₹1+ VAP increases were announced only on July 15 — well after Q1 close — suggesting the inflation wasn't fully priced in advance.

₹ per liter YoY change, Q1 FY27 vs Q1 FY26
01.462.914.373.9Procurement cost2.2Sales price increase1.7Unrecovered spread
Pricing lag: only ₹2.2 of ₹3.9 in cost inflation was passed through in Q1.

What management claimed vs. what holds up

Claims from the earnings call
  • "Margin pressure is cyclical; expect recovery Q2 onwards"

  • "Prices not fully passed; will gradually pass to consumers in forthcoming quarters"

  • "Highest-ever quarterly revenue of ₹1,198 crores, 19% YoY"

  • "India standalone milk procurement grew, ex-OSAM only 3%"

  • "VAP highest-ever sales of ₹415 crores, 17.6% growth; ex-bulk 40.6% growth"

  • "Africa delivered ₹154 crores revenue, 45.6% growth, EBITDA ₹24 crores up 74%"

The first claim — that this is cyclical — is overstated. A 280 basis point EBITDA miss against a 7–8% guidance target isn't seasonal noise; it's a structural execution gap. The second claim — gradual pass-through — is reality, but it came late. Revenue growth and VAP are solid. But India's core milk procurement grew only 3% ex-OSAM, a substantial deceleration from the 8–9% growth trajectory management had been guiding. Africa and VAP are carrying the growth story.

What changed on this call

Margin credibility weakened materially. The 7–8% EBITDA guidance for FY27 remains intact on the call, but management now explicitly pins recovery to Q2 onwards, admitting that Q1 fell short of internal expectations. This is a subtle but important shift: the guided recovery is now pushed out by one quarter, and will be measured against a new baseline (5.4%) rather than the prior-quarter expectation.

Core India growth decelerated. Analysts pressed hard on the 3% milk procurement growth ex-OSAM (Praveen Kumar, Equitas Capital, and others noted the slowdown from prior 8–9% guidance). Management's response: geographic selectivity. Dodla is not expanding aggressively in Tamil Nadu and Karnataka — regions with high cooperatives pricing gaps (₹10+ and ₹6–7 respectively) — because the risk-return doesn't work. Instead, it's focusing on Maharashtra (+10%) and geographic rotation into Bihar and eastern India. This is prudent, but it signals market maturity in core regions and acknowledges that price leadership has limits.

Africa and VAP remain the bright spots. Africa revenue reached ₹154 Cr (+45.6% YoY) with EBITDA of ₹24 Cr (+74%), and VAP (ex-bulk) grew 40.6%. Both delivered above consensus expectations and are driving the consolidated growth story. However, VAP's reported 17.6% growth masks a ₹57 Cr bulk sales exit (a one-time, non-repeatable decline). The cleaner metric is the 40.6% ex-bulk growth in lower-temperature logistics (LTL), which is sustainable but small in absolute magnitude.

The bull-bear ledger

  • Revenue +19% YoY, highest-ever ₹1,198 Cr; volume growth 13% in milk procurement

  • Africa scaled to ₹154 Cr with 45.6% growth and EBITDA now a ₹24 Cr contributor

  • VAP ex-bulk growing 40.6%, highest-ever ₹415 Cr sales; mix shift towards premium working

  • Balance sheet net debt-free with ₹689 Cr cash, funding ₹590 Cr capex without leverage

  • Price hikes initiated from July 15; management plans ₹2–2.5% additional milk hikes in Q2 and 3–4% VAP hikes

  • PAT crashed 35% YoY to ₹41 Cr; EBITDA margin fell 280 bps to 5.4%, missing 7–8% guidance materially

  • Pricing lag: only 56% of procurement cost inflation passed through; 44% absorbed into margin

  • Core India milk procurement only 3% growth ex-OSAM; market saturation and geographic constraints acknowledged

  • Margin recovery depends entirely on Q2+ price pass-through success; if elasticity kicks in or competitors slow to follow, volume growth at risk

  • Management credibility on guidance weakened by 280 bps EBITDA miss and reactive (not proactive) pricing response

Risks, ranked by holder impact

Ranked by severity to equity holders

Pricing power erosion if competitors follow milk price hikes selectively

High

Dodla's 4–5% FY27 pass-through plan assumes consumers will accept price hikes without volume elasticity. But Amul and Mother Dairy are lagging in the North and are cooperatives-subsidized in many regions. If they take hikes late or selectively, Dodla's volume growth (targeting 8–10%) could compress to low-single digits.

Procurement cost persistence if monsoon disruption continues

High

Management assumes normalization to ₹41/L (already high vs historical), but May–June–July prices were all flat around ₹41.20/L with no seasonal relief yet. If El-Niño impacts extend, milk supply stays tight, and costs remain elevated, the 7–8% EBITDA recovery guidance will miss again in Q2, eroding credibility further.

Core India growth deceleration becoming structural, not cyclical

Medium

3% milk growth ex-OSAM is material slowdown from 8–9%. Geographic rotation into lower-competitive areas (Bihar, eastern India) takes time to scale and may not offset saturation in core regions (TN, KA). If India's contribution continues to fade, consolidated growth depends increasingly on Africa and VAP, which are smaller bases.

Margin miss credibility: if Q2 EBITDA margin doesn't return to 7–8% range, guidance framework collapses

High

A second consecutive miss (after 280 bps miss in Q1) will signal that management's macro assumptions (procurement normalization, seasonal tailwinds, gradual price pass) are unreliable. Investors will demand a lower guidance range, compressing valuation multiples.

Working capital pressure if procurement costs stay elevated and inventory builds

Low

If milk supply remains muted (weak flush season) and company needs to hold inventory at high procurement costs, or become a net buyer, working capital strains emerge. However, ₹689 Cr cash and very short DSO (1.5–2 days) provide substantial buffer.

OSAM profitability stalling if cost pass-through fails in value-added segment

Medium

OSAM is experiencing raw material inflation similar to core business. If its own margin squeeze persists, the acquisition (₹250 Cr goodwill amortization in P&L) becomes a profit drag rather than an earnings accretor. At present, profitability improving but far from normalized.

How the street is positioned (and what it's saying)

Price action tells a clear story of disappointment. Dodla closed at ₹1042 as of July 31, and the day-1 post-result reaction was a 3.64% decline (from a pre-result close of ₹1070). The sell-off has held: by day 5, the stock was down 2.62% from the pre-result close. This is not a knee-jerk dip that faded on buybacks or short-covering; it's a considered repricing downward as the street digested the 35% PAT decline and 280 bps EBITDA miss.

Valuation context: The stock is now trading at ₹1042, down 23.94% from its all-time high of ₹1370 and below its 20-day, 50-day, and 200-day moving averages (₹1083.43, ₹1092.28, ₹1145.84 respectively). The RSI is neutral at 34.1 — not oversold, but not showing strength. Volume is increasing on the decline, consistent with institutional unwinding.

Institutional flows show a divergence: Foreign institutional investors (FII) are in retreat: ownership fell from 10.03% in Q1 FY-2026 to 6.43% in Q4 FY-2026 — a 357 basis point decline. Conversely, domestic institutional investors (DII) are adding: ownership rose from 19.21% to 25.34% — a 613 basis point increase. This pattern — FII exit, DII add — suggests foreign investors are rotating out of the story (likely citing margin miss and margin recovery uncertainty), while domestic buyers are accumulating at lower prices (possibly on a belief that the 7–8% guidance is attainable). Promoter ownership remains stable at ~59%, showing no insider selling pressure near the highs.

In sum: the street's verdict (price action + flows) aligns with the fundamental read — cautious skepticism on the margin recovery story, but not panic-selling. The 23.94% drawdown from ATH is material, but not capitulation. This is an opportunity repricing, conditional on Q2 execution.

The debate

What to watch next
  • 1 · Q2 FY-2027 price hike execution and volume resilience

    Management plans ₹2–2.5% milk and 3–4% VAP hikes in Q2. The pass-through test is whether demand elasticity emerges (volume growth stays 8–10%) or whether consumers trim purchases. This quarter resolves the bull-bear debate.

  • 2 · Procurement cost stabilization

    May–June–July prices were flat at ₹41.20/L; no seasonal relief yet. Normalization assumption is that costs stay at elevated ₹41/L (not decline). If monsoon impacts persist, cost stays high, margin recovery is pushed further out.

  • 3 · Competitive pricing response from Amul and Mother Dairy

    So far they're lagging Dodla's hikes (TN gap ₹10+, KA gap ₹6–7 persist). If they accelerate price matching in H2, Dodla's margins benefit (industry-wide pass-through). If they stay selective or subsidized, Dodla's pricing power is limited and volume risk rises.

  • 4 · Core India DDL growth stabilization

    3% growth is below guidance. If Maharashtra ramp and geographic rotation into Bihar show lift in H1 results, the deceleration narrative reverses. If core India stays stuck in low-single digits, consolidated growth depends entirely on Africa and VAP (smaller bases).

  • 5 · EBITDA margin trajectory in Q2 FY-2027

    The single most important number. If EBITDA margin returns to 7–8% range, credibility is restored and the stock re-rates higher. If it stays below 6.5%, guidance collapses and multiples compress further.

The number to track from here

Dodla Dairy is in the middle of a critical test: can it pass through procurement cost inflation without losing volumes? Q1 showed only a 56% pass-through, well behind the 100% needed to protect margins. The call reassured that price hikes are underway and recovery is imminent — but execution gap is evident, and the street has repriced the stock down 23.94% from its high.

This is not a collapse-and-recovery story (yet). Revenue momentum is real, Africa is working, and the balance sheet is fortress-like. But profit resilience is in question, and guidance credibility has taken a hit. Earnings are steady-state, not step-change — and the single number that matters from Q2 onwards is EBITDA margin. If it recovers to 7–8%, the drawdown becomes a buying opportunity. If it stays compressed, the recovery narrative is broken, and multiples will settle lower.

Hold, but monitor Q2 price pass-through and margin recovery closely. The next quarter is the truth test.

Informational and educational content only. Not investment advice.